Earlier this year, Ecolab’s Bioquell HPV-AQ 35% hydrogen peroxide disinfectant received an approval opinion from the European Chemicals Agency (ECHA) Biocidal Products Committee (BPC) for a Union Authorisation.
We are pleased to communicate that the approval has been officially published in the Official Journal of the European Union and thus written into European law, with Bioquell HPV-AQ given the approval number EU-0027469-0000.
Click here to download the PDF version of this story from the Clinical Services Journal. Due to pressures from highly contagious pathogens, healthcare facilities are seeking all-inclusive offerings to handle decontamination responsibilities and discovering unique solutions for creating private patient areas. Measures to help slow the spread of healthcare-associated infections (HCAIs), including COVID-19, require a […]Read More
In this Clinical Services Journal article, the topic of innovative decontamination efforts and hand hygiene tools are reviewed to show how they have helped hospitals raise infection control standards during the pandemic. Hospitals across the world saw cases rise while also dealing with unique challenges, whether PPE shortages, supply and staff issues, or finding effective […]Read More
Bioquell Rapid Bio Decontamination Service (RBDS) enables businesses to quickly regain control of clean spaces and ramp up capacity As the world prepares to enter the next phase of the COVID-19 pandemic with the potential relaxation of lockdown restrictions, Bioquell, an Ecolab solution and leading manufacturer of high performance bio-decontamination technology, is utilizing its well-proven […]Read More
Following the COVID-19 lockdown, environmental monitoring at a major international provider of Biologics Contract Development and Manufacturing Organisations (CDMO) services in Wuhan, China indicated spore contamination in a production room. Despite exhausting all disinfection methods in its records, including the manual application of a sporicide, there was a repeated failure of the EM test standards. […]Read More
During the COVID-19 pandemic, many hospital wards were temporarily converted to solely treat COVID-19 patients. As these begin to revert back to ‘regular’ non COVID-19 wards, a solution is required to manage the increased potential contamination risk facing the patients admitted to these wards. Our latest case study highlights how Bioquell’s RBDS recently returned an […]Read More
One of New Zealand’s largest hospitals has chosen to purchase their first Bioquell BQ-50 suite to help them combat COVID-19. The hospital is well versed in performing airborne disinfection with alternative technologies but has selected Bioquell to improve their decontamination capabilities. The Bioquell BQ-50 has been chosen due to its emphasis on operator and patient […]Read More
A hospital in Kent has recently purchased 3 Bioquell PODs after identifying that their current set-up was not adequate for viral or bacterial infection outbreaks. The plan is to transform part of their High Dependency Unit into segregated areas using the Bioquell PODs. The Bioquell POD is an ideal solution for converting open wards to […]Read More
Bioquell hydrogen peroxide vapor technology has been used in Duke’s latest study. See a link to the study and other news here: https://www.dukechronicle.com/article/2020/03/duke-health-researchers-decontaminate-n95-face-masks-reuseRead More
Bioquell, an Ecolab Solution, is in the news as the FDA grants an Emergency Use Authorization (EUA) for Battelle and its CCDS Critical Care Decontamination System. See the full story here about the efforts taking place with this a Columbus-based non-profit. Read more on USA Today.Read More